ArticleClinical Medicine Insights. Oncology2023
Is the Urinary and Gut Microbiome Associated With Bladder Cancer?
Article in Clinical Medicine Insights. Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 17 citations in OpenAlex.
- Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation.iMetaOmics · 2026Review
- Integrative multi-cohort analysis identifies urinary microbiota as non-invasive biomarkers of bladder cancer.BMC microbiology · 2026Article
- Research advances on the urinary microbiome in non-infectious urinary tract diseases: from community composition to clinical prospects.Frontiers in cellular and infection microbiology · 2026Review
- Impact of the urinary microbiome on urinary tract infection progression.Central European journal of urology · 2026Review
- Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential.Frontiers in cellular and infection microbiology · 2026Review
- Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.Frontiers in immunology · 2026Review
- Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.Frontiers in microbiology · 2026Review
- Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer.Journal of microbiology (Seoul, Korea) · 2025Review
- The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer.International journal of molecular sciences · 2025Review
- Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Microbiome Shifts in Bladder Cancer: A Narrative Review of Urobiome Composition, Progression, and Therapeutic Impact.Medicina (Kaunas, Lithuania) · 2025Review
- Streptococcus anginosus: the potential role in the progression of gastric cancer.Journal of cancer research and clinical oncology · 2025Review
- Gut microbiota, blood metabolites, & pan-cancer: a bidirectional Mendelian randomization & mediation analysis.AMB Express · 2025Article
- The Urogenital System Microbiota: Is It a New Gamechanger in Urogenital Cancers?Microorganisms · 2025Review
- Comparison of the microbiome of bladder urine, upper urinary tract urine, and kidney stones in patients with urolithiasis.Central European journal of urology · 2025Article
- Insights into the Interplay between the Urinary Microbiome and Bladder Cancer: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Current Trends and Challenges of Microbiome Research in Bladder Cancer.Current oncology reports · 2024Review
- Change in microbiota profile after vaginal estriol cream in postmenopausal women with stress incontinence.Frontiers in microbiology · 2024Article
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microbiome dysbiosis plays a role in the pathogenesis of many urological diseases, including bladder cancer (BC). The aim of the study was to compare the urinary and gut microbiota of patients with BC with a healthy control (HC) group. Methods: The study group included patients hospitalized in 2020 to 2021 with diagnosed BC and HC. Prior to the transurethral resection of bladder tumor, patients collected their urine and stool which was then subjected to 16S rRNA gene sequencing. Results: Overall, 25 patients were enrolled in the study: 18 in the BC group and 7 in the HC group. Analysis of the urine and stool microbiome showed no statistically significant differences between patients with BC and HC in alpha diversity, beta diversity, and difference in taxa relative abundance. Detailed analysis of urine and stool microbiome depending on patient- and tumor-related characteristics also showed no statistically significant differences in alpha diversity and beta diversity. Differences in abundance (ANCOM) were noted in both types of samples in patients with BC. In the urine test, genus Conclusions: The microbiome of urine and stool of patients with BC does not differ significantly from that of HC; however, its composition in patients with BC varies according to the patient's sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.